Drug updated on 12/11/2024
| Dosage Form | Tablet (oral; 2 mg) |
| Drug Class | Sphingosine 1-phosphate receptor modulators |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of moderately to severely active ulcerative colitis in adults.
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- In treat-through patients with ulcerative colitis, etrasimod 2 mg/day was ranked highest in efficacy, with a surface under the cumulative ranking (SUCRA) value of 91.1%.
- For patients with ulcerative proctitis, etrasimod was superior to placebo for both induction of remission (relative risk (RR) 4.71; 95% confidence interval (CI) 1.2-18.49) and maintenance of remission (RR 2.08; 95% CI 1.31-3.32).
- No specific safety concerns or adverse effects were mentioned for etrasimod in the reviewed documents.
- The studies focused on two specific subgroups: re-randomized patients and treat-through patients for ulcerative colitis, as well as patients with ulcerative proctitis (UP). Etrasimod 2 mg/day showed the highest efficacy for treat-through patients with ulcerative colitis, and it was also effective for both induction and maintenance of remission in UP patients compared to placebo.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Velsipity (etrasimod) Prescribing Information. | 2024 | Pfizer Inc., New York, NY |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Comparative maintenance performance of all biologic agents and small molecules in ulcerative colitis: a network meta-analysis | 2024 | European Journal of Gastroenterology & Hepatology |
| Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis | 2023 | Alimentary Pharmacology & Therapeutics |